What are the recommended acyclovir dosing adjustments for patients with impaired renal function (creatinine clearance ≤50 mL/min)?

Acyclovir Dose Adjustment in Renal Impairment

Acyclovir dosing must be reduced in patients with creatinine clearance ≤50 mL/min to prevent nephrotoxicity and neurotoxicity, with specific adjustments based on the degree of renal impairment. 1, 2

Standard Dosing in Normal Renal Function

• For herpes simplex encephalitis: 10 mg/kg IV every 8 hours for 14-21 days in adults with normal renal function 3, 1
• For varicella zoster virus encephalitis: 10-15 mg/kg IV every 8 hours (though 10 mg/kg is more commonly used to reduce nephrotoxicity risk) 1
• Oral acyclovir bioavailability is only 10-20% and decreases with increasing dose 2

Renal Dose Adjustment Requirements

The dose of acyclovir must be reduced in patients with pre-existing renal impairment, as both the half-life and total body clearance are dependent on renal function. 1, 2

Pharmacokinetic Rationale

• In patients with normal renal function (CrCl >80 mL/min), the mean half-life is 2.5 hours and clearance is 327 mL/min/1.73 m² 4
• In anuric patients on hemodialysis, the terminal half-life extends dramatically to 19.5 hours, with total body clearance reduced to only 28.6 mL/min/1.73 m² 5
• Acyclovir is almost entirely eliminated by the kidneys through glomerular filtration and tubular secretion 4

Specific Dosing Recommendations for End-Stage Renal Disease

For patients on continuous ambulatory peritoneal dialysis (CAPD) with varicella zoster infections, the loading dose should be 400 mg and the maintenance dose should be 200 mg twice daily. 6

• The currently recommended daily dose of 1,600 mg for end-stage renal disease patients leads to supratherapeutic levels, increasing the risk of neurotoxicity 7
• Computer modeling suggests that daily doses of 600-800 mg will achieve therapeutic levels (4-8 microM) in CAPD patients 7
• After a single 800 mg oral dose in anuric CAPD patients, peak plasma levels of 8.95 microM were achieved with a half-life of 14.52 hours 7

Hemodialysis Considerations

• Acyclovir is readily dialyzable with a mean extraction coefficient of 0.45 and dialysis clearance of 81.8 mL/min 5
• The terminal half-life during hemodialysis is reduced to 5.7 hours 5
• Dosage modifications are needed both to avoid accumulation between dialysis sessions and to replace dialyzed drug after each session 5

Nephrotoxicity Risk and Prevention

Mechanism and Risk Factors

• Acyclovir can cause acute kidney injury through crystalluria resulting in obstructive nephropathy, which is usually reversible 1, 8
• Risk is considerably higher with rapid IV bolus injection of high doses, but is reduced by slow infusion over one hour with adequate hydration 8
• Nephrotoxicity can occur within 48 hours of initiating standard doses, even in previously healthy patients 9
• Coadministration with other nephrotoxic agents increases the risk of renal dysfunction and CNS symptoms 2

Critical Monitoring

Regular renal function assessments are crucial, especially within the first 48 hours of treatment, as acute kidney injury can develop rapidly even at standard doses. 9

• Adequate hydration should be maintained throughout treatment 2
• Plasma urea or creatinine elevations occurred in 58 of 354 patients treated with IV acyclovir in early studies 8

High-Dose Considerations

• Higher doses (15 mg/kg every 8 hours) for VZV encephalitis carry increased nephrotoxicity risk 10
• Two cases of acute renal failure were reported after increasing acyclovir from 10 mg/kg to 15 mg/kg every 8 hours for VZV encephalitis 10
• Most clinicians use the 10 mg/kg dose to balance efficacy with safety, with renal function reviewed frequently 1

Special Populations

Geriatric Patients

• Acyclovir plasma concentrations are higher in geriatric patients due to age-related changes in renal function 2
• Dosage reduction may be required even with underlying mild renal impairment 2
• Age-related decreases in acyclovir clearance reflect age-related changes in renal function, so adjustments based on creatinine clearance will compensate for age effects 4

Neonates and Pediatric Patients

• In neonates, clearance is approximately one-third the adult value 4
• Median clearance varies from 0.2 to 1.0 L/h in subjects with post-menstrual age <34 or ≥34 weeks, respectively 11
• Exposure to acyclovir increases with decreasing post-menstrual age and renal function, suggesting different dosing requirements for pre-term neonates 11

Clinical Pitfalls to Avoid

• Do not use standard dosing in patients with any degree of renal impairment - even mild reductions in creatinine clearance require dose adjustment 1, 2
• Do not assume stable renal function - acute kidney injury can develop during treatment, requiring reassessment and further dose reduction 9
• Ensure adequate hydration - dehydration significantly increases nephrotoxicity risk 2, 8
• Avoid rapid IV bolus administration - always infuse over at least one hour 8